Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
Managing Neuropathic Pain
…oral medications for the treatment of neuropathic pain are gabapentinoids (such as gabapentin and pregabalin), serotonin norepinephrine reuptake inhibitors (SNRIs such as duloxetine and venlafaxine), tricyclic antidepressants (TCAs such as…
INC Research Study 6601
…progressed in people if the drug had not been administered. In essence, researchers are using this natural history to establish baselines against which the results of treatment regimens may be…
SORD Research
…some of the advances in the eventual treatment of axon degeneration may be applicable as these therapies are developed. If your type is not yet identified, please visit a CMTA…
CMT4 Research
…CMTA has given a venture philanthropy grant to Taysha Gene Therapies (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment…
The CMTA Mourns the Loss of Scientific Advisory Board Member and Esteemed CMT Clinical Researcher
…Laura Feltri will be deeply missed.” Dr. Feltri was a dedicated supporter of our mission to support the development of new treatments for CMT, to improve the quality of life…
CMTA Awards Over Half a Million Dollars to Fuel Research in Demyelinating Forms of CMT
…global leadership in advancing treatments for CMT and it underscores the association’s commitment to improving the lives of those who have CMT, while strengthening its dedication to developing treatments and,…
CMTA Updates List of Neurotoxic Meds Potentially More Hazardous to CMT Patients
…than for people who do not have CMT. The reviewers emphasized the importance of not denying patients with CMT treatments that may prolong life expectancy for cancer or improve their…
Vera Fridman, MD joins the CMTA STAR Advisory Board
…on paving the way for, and executing, treatment trials for neuropathy. Dr. Fridman’s research aims to address the barriers to effective clinical trials in Charcot-Marie-Tooth (CMT) disease through the execution…
CMTAreportFall2023forwebspreads
…further accelerate progress. The CMTA is committed to supporting clinical trial readiness and roll-out for CMT and we look forward to the next chapter of this treatment’s development.” DTx Pharma…
Gene Therapy Advances for CMT4J, CMT4A and GAN
…a gene therapy for one rare form of CMT called Giant Axonal Neuropathy, and aims to develop similar gene therapy treatments for other forms of CMT. Dr. Gray is a…